Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.

Autor: Ruggiu, Mathilde1, Oberkampf, Florence1, Ghez, David2, Cony-Makhoul, Pascale3, Beckeriche, Florence4, Cano, Isabelle1, Taksin, Anne L.1, Benbrahim, Omar5, Ghez, Stéphanie1, Farhat, Hassan1, Rigaudeau, Sophie1, de Gunzburg, Noémie1, Lara, Diane1, Terre, Christine6, Raggueneau, Victoria6, Garcia, Isabel6, Spentchian, Marc6, De Botton, Stéphane2, Rousselot, Philippe1,7 phrousselot@ch-versailles.fr
Zdroj: Leukemia & Lymphoma. Jul2018, Vol. 59 Issue 7, p1659-1665. 7p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje